在患有骨髓纤维化症的患者中,鲁克索利提尼布和心力衰竭的结果
Orly Leiva1, Steven Soo2,3, Olivia C Liu2
1Gill Heart & Vascular Institute, University of Kentucky College of Medicine, Lexington, KY, USA.
Leukemia & lymphoma
|March 5, 2026
概括
鲁克索利提尼布可能会降低骨髓纤维化 (MF) 患者的心力衰竭风险. 这种骨髓增殖性瘤 (MPN) 治疗显示,心力衰竭住院或新肺高血压的风险降低.
科学领域:
- 血液学 血液学 血液学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓纤维化 (MF) 是一种骨髓扩散性瘤 (MPN),与心力衰竭 (HF) 和肺高血压 (PH) 风险增加有关.
- 这些心血管并发症对多发性肺炎患者的发病率和死亡率有很大影响.
研究的目的:
- 研究ruxolitinib治疗对MF患者HF住院或新PH的风险的影响.
- 评估ruxolitinib对该队列所有原因死亡率的影响.
主要方法:
- 对144名没有先前患有HF的MF患者进行了回顾性队列研究.
- 分析的结果包括HF住院,新的PH和全因死亡.
- 统计分析使用调整后的次危险比率和危险比率.
主要成果:
- 卢克索利提尼布治疗与HF住院或新的PH (aSHR 0.27) 的风险明显降低.
- 鲁克索利提尼布与所有原因死亡 (aHR 0.85) 之间没有发现显著的关联.
结论:
- 卢克索利提尼布治疗可能会减少MF患者心血管并发症.
- 需要进一步的前性随机研究来证实这些发现,并确定ruxolitinib在改善多发性肺炎患者心血管结果方面的作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure V: Medical Management
439
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
439
Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure III: Clinical Manifestations
734
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
734
Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K

